1-20 of 67
Melhem Solh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Shernan G Holtan, Mehdi Hamadani, Juan WU, Monzr M. AL Malki, Lyndsey Runaas, Hany Elmariah, Andrew R. Rezvani, Mahasweta Gooptu, Karilyn T. Larkin, Brian C. Shaffer, Najla H El Jurdi, Alison W. Loren, Melhem Solh, Aric C. Hall, Amin M Alousi, Omer H Jamy, Miguel-Angel Perales, Janny M. Yao, Kristy Applegate, Ami S. Bhatt, Leslie S. Kean, Yvonne A. Efebera, Carrie Lynn Kitko, Ran Reshef, William Clark, Nancy L. DiFronzo, Lori Henderson, Richard J. Jones, Eric Liefer, Michael J Martens, Mary M. Horowitz, Javier Bolanos-Meade
Journal: Blood
Blood (2022) 140 (Supplement 2): LBA-4.
https://doi.org/10.1182/blood-2022-171463
Published: 2022
Journal Articles

A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)

Brian T. Hess, Graham P. Collins, Melhem Solh, Mitul Gandhi, Ying Wang, Yajuan Qin, Eric Yu, Pier Luigi Zinzani
Journal: Blood
Blood (2022) 140 (Supplement 1): 12079–12080.
https://doi.org/10.1182/blood-2022-163277
Published: 2022
Journal Articles

Vitalize Trial: A Phase 2b, Open-Label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of the Novel Immunotherapeutic, Maveropepimut-S, and Pembrolizumab with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew J. Matasar, Eric Lee, Sophie Leitch, Melhem Solh, Jennifer Teti, Kabir Mody, Stephan Fiset, Jeremy Graff
Journal: Blood
Blood (2022) 140 (Supplement 1): 12073–12074.
https://doi.org/10.1182/blood-2022-159000
Published: 2022
Journal Articles

Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, H. Kent Holland, Lawrence E. Morris, Jr., Asad Bashey, Melhem Solh
Journal: Blood
Blood (2022) 140 (Supplement 1): 7647–7648.
https://doi.org/10.1182/blood-2022-162788
Published: 2022
Journal Articles

Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center

Asad Bashey, Xu Zhang, Scott R. Solomon, Lizamarie Bachier-Rodriguez, H. Kent Holland, Lawrence E. Morris, Jr., Melhem Solh
Journal: Blood
Blood (2022) 140 (Supplement 1): 7568–7569.
https://doi.org/10.1182/blood-2022-156852
Published: 2022
Journal Articles

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

Scott R. Solomon, Melhem Solh, Lawrence E. Morris, Jr., H. Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Caitlin Guzowski, Katelin C Jackson, Stacey Brown, Asad Bashey
Journal: Blood
Blood (2022) 140 (Supplement 1): 1188–1189.
https://doi.org/10.1182/blood-2022-158797
Published: 2022
Journal Articles

HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Melhem Solh, Michael T Aubrey, Xu Zhang, Asad Bashey, Brian M Freed, Christina L Roark, Lizamarie Bachier-Rodriguez, Lawrence E. Morris, Jr., H. Kent Holland, Scott R. Solomon
Journal: Blood
Blood (2022) 140 (Supplement 1): 7738–7739.
https://doi.org/10.1182/blood-2022-164804
Published: 2022
Journal Articles

Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program

Asad Bashey, Xu Zhang, Melhem Solh, H. Kent Holland, Lawrence E. Morris, Jr., Lizamarie Bachier-Rodriguez, Scott R. Solomon
Journal: Blood
Blood (2022) 140 (Supplement 1): 11007–11008.
https://doi.org/10.1182/blood-2022-163574
Published: 2022
Journal Articles

Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus

Melhem Solh, Scott R. Solomon, Xu Zhang, Lawrence E. Morris, Jr., Lizamarie Bachier-Rodriguez, H. Kent Holland, Asad Bashey
Journal: Blood
Blood (2022) 140 (Supplement 1): 4745–4746.
https://doi.org/10.1182/blood-2022-164773
Published: 2022
Journal Articles

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar Jacques Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Yair Levy, Michael H Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P Chu, Cristina J. Gasparetto, Andrew P. Dalovisio, Michael Sebag, Alexander M Lesokhin
Journal: Blood
Blood (2022) 140 (Supplement 1): 388–390.
https://doi.org/10.1182/blood-2022-166494
Published: 2022
Journal Articles

TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, Asad Bashey, Lawrence E. Morris, Jr., H. Kent Holland, Melhem Solh
Journal: Blood
Blood (2022) 140 (Supplement 1): 10618–10619.
https://doi.org/10.1182/blood-2022-158803
Published: 2022
Journal Articles

Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, Michael T. Aubrey, Christina L. Roark, Lawrence E. Morris, Jr., H. Kent Holland, Asad Bashey, Melhem Solh
Journal: Blood
Blood (2022) 140 (Supplement 1): 4861–4862.
https://doi.org/10.1182/blood-2022-158759
Published: 2022
Journal Articles

Real-World Data on the Incidence and Management of Blinatumomab Toxicities in Adult Patients with Minimal Residual Disease and Relapsed or Refractory Acute Lymphoblastic Leukemia

Rebecca Farley, Eva Karam, Xu Zhang, Asad Bashey, H. Kent Holland, Lawrence E. Morris, Jr., Scott R. Solomon, Melhem Solh
Journal: Blood
Blood (2022) 140 (Supplement 1): 11694–11695.
https://doi.org/10.1182/blood-2022-167938
Published: 2022
Journal Articles

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Juan Pablo Alderuccio, Russ A Kuker, Isildinha M Reis, Muthiah Nachiappan, Brad S. Kahl, Mehdi Hamadani, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Brian T. Hess, Matthew A. Lunning, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Eric Yu, Paolo F Caimi, Deukwoo Kwon, Izidore S. Lossos, Fei Yang, Craig H. Moskowitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 6650–6652.
https://doi.org/10.1182/blood-2022-162758
Published: 2022
Journal Articles

Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse

Melhem Solh, Asad Bashey, Scott R. Solomon, Lawrence E Morris, Xu Zhang, H. Kent Holland
Journal: Blood
Blood (2021) 138 (Supplement 1): 3928.
https://doi.org/10.1182/blood-2021-151331
Published: 2021
Journal Articles

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Michael Sebag, Noopur S. Raje, Nizar J. Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Y. Levy, Michael H. Tomasson, Harman Dube, Michael A. Damore, Hoi Ken Lon, Cynthia Basu, Athanasia Skoura, Edward Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P. Chu, Cristina Gasparetto, Andrew P. Dalovisio, Alexander Lesokhin
Journal: Blood
Blood (2021) 138 (Supplement 1): 895.
https://doi.org/10.1182/blood-2021-150519
Published: 2021
Journal Articles

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Alice S. Mims, Melhem Solh, Jennifer N. Saultz, Uma Borate, Naveen Pemmaraju, Gautam Borthakur, Gail J. Roboz, Ben Powell, Bernice Matusow, Jason Halladay, Shireen Vali, Chelsea L. Hope, Madan G. Kundu, Ching Hsu, Paul Watkins, Chao Zhang, Jackie M. Walling, Athanasios C. Tsiatis, Amy E. DeZern
Journal: Blood
Blood (2021) 138 (Supplement 1): 3420.
https://doi.org/10.1182/blood-2021-152040
Published: 2021
Journal Articles

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial

Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3575.
https://doi.org/10.1182/blood-2021-148730
Published: 2021
Journal Articles

Impact of Choice of Induction Regimen on Overall Survival and Post-Remission Survival Among Older Adults with Acute Myeloid Leukemia

Kelli McCrum, Justin LaPorte, Asad Bashey, Scott R. Solomon, Lawrence E Morris, H. Kent Holland, Melhem Solh
Journal: Blood
Blood (2021) 138 (Supplement 1): 2329.
https://doi.org/10.1182/blood-2021-151422
Published: 2021
Journal Articles

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy

Paolo F. Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Z. Ai, Matthew A. Lunning, Jasmine Zain, Melhem Solh, Brad S. Kahl, Mehdi Hamadani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2489.
https://doi.org/10.1182/blood-2021-153591
Published: 2021